FL-LUMOS-DIAGNOSTICS
Lumos Diagnostics announced the closing of U.S. $15 million in Series A funding from Planet Innovation , an Australia-based healthtech innovation and commercialization company. This funding will support the international commercial expansion of the FebriDx® rapid point-of-care (POC) test, the FebriDx U.S. FDA pivotal clinical trial, and additional development and manufacturing resources for the company’s expanding full-service POC business.
Lumos Diagnostics, a spinout from Planet Innovation, merged with RPS Diagnostics in May 2019, creating a diverse healthcare company that combines the FebriDx test and commercial experience with a novel and proprietary digital reader platform. Sam Lanyon, chairman of the board for Lumos Diagnostics and co-chief executive officer for Planet Innovation states, “Planet Innovation is focused on breakthrough technology and making investments that will have a global impact on healthcare. It is obvious that Lumos Diagnostics is poised for rapid growth and Planet Innovation is keen to support and accelerate the process.”
FebriDx is a rapid POC test that provides clinicians with an in-office assessment of the body’s immune response to acute respiratory infection (ARI). More than 50% of all unnecessary antibiotic prescriptions are for outpatient ARIs which may be associated with nonspecific flu-like symptoms, including fever, sore throat, cough, nasal congestion and fatigue. Only bacterial infections benefit from antibiotic treatment. The single-use FebriDx test identifies patients of all ages within 10 minutes who have a clinically significant underlying infection and aids in the differentiation of viral and bacterial ARIs through the simultaneous detection of both Myxovirus resistance protein A (MxA) and C-reactive protein (CRP) directly from a fingerstick blood sample.
MxA is highly specific and elevates in the presence of acute viral infection while CRP is a nonspecific inflammatory protein that elevates in the presence of clinically significant infection. The simultaneous, combined interpretation of both MxA and CRP leads to sensitive and specific test results. With a 97-99% negative predictive value for ruling out bacterial infections, the FebriDx test may help to limit the amount of unnecessary antibiotic prescriptions that can lead to avoidable adverse reactions and antibiotic resistance, resulting in lower costs.
Robert Sambursky, MD, president and chief executive officer of Lumos Diagnostics states, “FebriDx helps advise antibiotic decisions for outpatient ARI while saving clinician time, improving workflow and reducing overall costs. The novel digital reader technology that Lumos offers as part of our complete POC service solution will be used in the next generation digital FebriDx test, providing faster time to results, identification of the rare co-infection and enhanced objectivity of test result interpretations.”
Lumos Diagnostics
Lumos Diagnostics provides rapid, cost-effective and complete point-of-care (POC) diagnostic test solutions that utilize proprietary digital reader platforms to help healthcare professionals more accurately diagnose and manage diseases and medical conditions. Lumos provides assay development and manufacturing services for customized POC tests as well as directly develops, manufactures and will commercialize a suite of proprietary Lumos-branded POC tests that focus on the systemic host immune response. Lumos’s tests target infectious and inflammatory diseases with unmet diagnostic needs. Actionable results lead to less unnecessary treatments with associated adverse events, reduced spread of disease and more effective clinical management and therapeutic decisions.
The FebriDx test has received HealthCanada approval, Saudi Arabia FDA clearance, Singapore HSA registration, Pakistan DRAP registration and is CE marked for sale in Europe. At this time, FebriDx has not received U.S. Food and Drug Administration (FDA) clearance and is not commercially available in the United States. For more information on Lumos Diagnostics, visit www.lumosdiagnostics.com , and for more information on FebriDx, visit www.febridx.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200205005031/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Kinaxis and Ottawa Senators Renew Partnership, Uniting National Capital Region26.6.2025 20:32:00 CEST | Press release
Bold partnership focuses on elevating community impact and brand presence Kinaxis® (TSX:KXS), a global leader in end-to-end supply chain orchestration, is proud to announce a renewed three-year partnership with the Ottawa Senators and their AHL affiliate, the Belleville Senators. This collaboration is designed to amplify Kinaxis’ brand visibility, deepen community roots, and create unforgettable experiences for customers, prospects, and employees. As two proud Ottawa-based organizations, Kinaxis and the Senators will come together again to celebrate local talent, foster youth development, and drive meaningful community engagement. The partnership will also spotlight the Kinaxis brand across high-visibility platforms—including center ice at Canadian Tire Centre, LED rings, and digital dashboards during home and away games—ensuring a powerful presence throughout the NHL season. “At Kinaxis, we believe in the power of community and the importance of showing up where it matters most,” said
CB Insights Unveils Industry's First AI Agent Workforce for M&A, Partnerships, Competitive Intelligence, Deal Sourcing, GTM, and More26.6.2025 18:49:00 CEST | Press release
Purpose-built agents work around the clock to deliver external intelligence that transforms how enterprises make strategic decisions CB Insights, the leading provider of predictive market intelligence, today announced the launch of its Team of Agents – the industry's first comprehensive AI agent workforce designed specifically to enable business leaders with always-on market intelligence for strategic decision-making. CB Insights’ growing team of agents starts with 11 specialized agents that work continuously to uncover insights, translate proprietary data into action, and accelerate smart decisions by providing the external intelligence layer that enterprises need to compete effectively across business development, investments, partnerships, GTM, and competitive intelligence. While generic AI assistants struggle with business context and lack reliable external data, CB Insights' Team of Agents delivers validated intelligence and data science on over 10 million companies and 1,500 tech
Pure Lithium and CEO Emilie Bodoin Recognized for Innovations at Reuters Global Energy Transition Awards26.6.2025 18:27:00 CEST | Press release
Pure Lithium Corporation, a disruptive vertically integrated lithium metal battery technology company, is pleased to announce that it has won the 2025 Reuters Global Energy Transition award for R&D Achievement. The award, presented at a June 24th ceremony in New York, recognizes research and development projects that promote a science-oriented energy transition while yielding promising potential and achievement. Pure Lithium has developed lithium metal batteries with double the energy density of lithium-ion cells and an industry-leading cycle life. By prioritizing research and development, the company achieved step-change advancements in battery technology and has built a strong portfolio of 119 patents and applications. “We’re thrilled to be selected for this prestigious award, which recognizes the hard work, dedication and creativity of our world-class team,” said Pure Lithium Founder and CEO Emilie Bodoin. “We know that commercializing a new chemistry requires a delicate balance of
Ant Group Launches AI Healthcare App AQ Amid Push into Healthcare Sector26.6.2025 16:41:00 CEST | Press release
Digital leader aims to capture rising cross-generational demand for public and private healthcare services amid demographic shift and urbanization trends.The launch of AQ enhances Ant Group’s comprehensive suite of AI solutions for healthcare, enabling medical institutions and doctors to offer more efficient, accessible, and personalized services. Ant Group today launched its AI healthcare app, AQ, to accelerate the company’s entry into the healthcare sector. The app helps users manage their daily healthcare needs with over 100 AI-powered services, including doctor recommendations, medical report analysis, and personalized medical advice. It also connects users to digital services from over 5,000 hospitals and nearly 1 million doctors across China. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250626728870/en/ Ant Group launched the AI healthcare app AQ to accelerate its entry into the healthcare sector By around 2035, over
Wasabi Technologies Becomes Official Cloud Storage Partner and Front-of-Jersey Sponsor of USA Rugby26.6.2025 16:00:00 CEST | Press release
USA Rugby partnership marks the latest addition to Wasabi’s robust sports sponsorship portfolio Wasabi Technologies, the hot cloud storage company, today announced it has strengthened its sports sponsorship program as the Official Cloud Storage Partner of USA Rugby. This milestone partnership unites two organizations committed to rapid growth, excellence, and technology innovation. Wasabi is purpose-built for media-rich industries like sports and entertainment and offers simple, fast, and predictable cloud storage for organizations with growing content archives. USA Rugby now stands alongside Wasabi’s compelling sponsorship portfolio of teams unlocking the power of their data, including iconic organizations, like the Boston Red Sox and Liverpool Football Club. “With digital transformation being top of mind for all sports organizations, we can’t think of a better partner than Wasabi to innovate alongside,” said USA Rugby CEO, Bill Goren. “Wasabi has established itself as a true industry
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom